Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy? by Prestwich, Robin J et al.
Clinical Medicine: Oncology 2008:2 83–96 83
REVIEW
Correspondence: Dr. Robin J Prestwich, Level 5, Welcome Trust Brenner Building, St. James’s University 
Hospital, Beckett Street, Leeds, LS9 7TF, UK. Tel: 0044 131 3438450; Fax: 0044 113 3438501; 
Email: r.j.d.prestwich@leeds.ac.uk
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the 
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.
Oncolytic Viruses: Do They Have a Role in Anti-Cancer 
Therapy?
1Robin J Prestwich, 
1Fiona Errington, 
2,3Kevin J. Harrington, 
4Hardev S. Pandha, 
1Peter Selby and 
1Alan Melcher
1Cancer Research UK, St James’s University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
2Targeted Therapy Laboratory, Institute of Cancer Research, Cancer Research UK. Centre for Cell 
and Molecular Biology, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK.
3Head and Neck Unit, Royal Marsden Hospital, 203 Fulham Road, London SW3 6JJ, UK. 
4Oncology, Postgraduate Medical School, University of Surrey, Guildford, GU2 7XX, UK.
Abstract: Oncolytic viruses are replication competent, tumor selective and lyse cancer cells. Their potential for anti-cancer 
therapy is based upon the concept that selective intratumoral replication will produce a potent anti-tumor effect and pos-
sibly bystander or remote cell killing, whilst minimizing normal tissue toxicity. Viruses may be naturally oncolytic or be 
engineered for oncolytic activity, and possess a host of different mechanisms to provide tumor selectivity. Clinical use of 
live replicating viruses is associated with a unique set of safety issues. Clinical experience has so far provided evidence of 
limited efﬁ  cacy and a favourable toxicity proﬁ  le. The interaction with the host immune system is complex. An anti-viral 
immune response may limit efﬁ  cacy by rapidly clearing the virus. However, virally-induced cell lysis releases tumor asso-
ciated antigens in a ‘dangerous’ context, and limited evidence suggests that this can lead to the generation of a speciﬁ  c 
anti-tumor immune response. Combination therapy with chemotherapy or radiotherapy represents a promising avenue for 
ongoing translation of oncolytic viruses into clinical practice. Obstacles to therapy include highly effective non-speciﬁ  c 
host mechanisms to clear virus following systemic delivery, immune-mediated clearance, and intratumoral barriers limiting 
virus spread. A number of novel strategies are now under investigation to overcome these barriers. This review provides an 
overview of the potential role of oncolytic viruses, highlighting recent progress towards developing effective therapy and 
asks if they are a realistic therapeutic option at this stage.
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Introduction
The anti-tumor activity of viruses has been observed throughout the 20th century. Viral infections were 
noted to precede apparently inexplicable cancer remissions in multiple case reports of spontaneous 
remissions (Bluming and Ziegler, 1971; DePace, 1912; Hansen and Libnoch, 1978). Viruses were tested 
as anti-cancer agents in the 1950’s, before research into this ﬁ  eld was widely abandoned due to a lack 
of efﬁ  cacy and toxicity concerns (Kelly and Russell, 2007). More recent scientiﬁ  c developments in the 
ﬁ  elds of virology, genetic manipulation, molecular and cell biology have provided insights into the 
mechanisms by which viruses may selectively infect cancer cells, and of how viruses may be manipu-
lated to enhance their anti-cancer activity. In 1991, the anti-tumor activity of herpes simplex virus was 
demonstrated in a murine glioma model (Martuza et al. 1991), and was followed by a resurgence of 
interest in the use of viruses as novel cancer therapy. A host of viruses have subsequently been inves-
tigated for their oncolytic activity, and several have entered clinical trials over the last 10 years (Aghi 
and Martuza, 2005).
Oncolytic viruses are self-replicating, tumor selective and lyse cancer cells following viral infection. 
Non-oncolytic non-replicating viruses, in contrast, may also be used in cancer therapy, but as vectors to 
deliver gene therapy. Oncolytic viruses are dependant upon the host for replication, and differences in 
the cellular processes of normal host cells and tumor cells provide the potential for tumor-selective rep-
lication. Characteristics of cell transformation, including increased cell cycling, oncogene activation, 
altered receptor expression and defective signalling pathways, have been shown to enhance the ability 
of some viruses to replicate in neoplastic cells (Stojdl et al. 2000; Barber, 2005; Shmulevitz et al. 2005). 84
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Oncolytic viruses may be tumor selective in their 
wild type or attenuated forms, or may be genetically 
modiﬁ  ed to provide or enhance tumor selectivity 
(Parato et al. 2005). The potential utility of onco-
lytic viruses as anti-cancer therapy is based upon 
the concept that replication of the virus within the 
tumor will amplify viral load and enhance anti-
tumor potency, whilst tumor selectivity will provide 
a favourable toxicity proﬁ  le, sparing normal tissues. 
Non-overlapping mechanisms of action and toxic-
ity proﬁ  les will allow combination with standard 
therapies. In addition, although the anti-tumor activ-
ity of oncolytic viruses is conventionally considered 
to be mediated via the direct actions of the virus 
upon tumor cells, there is emerging evidence that 
tumor infection can lead to the generation of an 
effective anti-tumor immune response (Diaz et al. 
2007; Moehler et al. 2005; Greiner et al. 2006; 
Schirrmacher, 2005).
Signiﬁ  cant obstacles need to be overcome in 
the design of effective oncolytic virus treatment 
schedules. Locally administered virus does not 
generally spread to other tumor sites (Liu and Kirn, 
2007), and systemically administered virus is 
highly susceptible to efﬁ  cient immune and non-
immune mediated clearance mechanisms (Fisher, 
2006). Even if tumor infection is successfully 
achieved, physical barriers within the tumor envi-
ronment prevent efﬁ  cient infection throughout the 
tumor. Modiﬁ  cation of viruses to provide tumor 
selectivity and to minimise toxicity may reduce 
anti-tumor potency (Gunzburg, 2005). In addition, 
signiﬁ  cant safety concerns exist regarding the use 
of replication competent viruses (Chernajovsky 
et al. 2006). Viruses do not adhere to conventional 
toxicity and dose-response relationships, and opti-
mum dose schedules remain unresolved (Aghi and 
Martuza, 2005).
This review aims to provide an introduction to 
the potential of oncolytic viral therapy, highlight-
ing progress in understanding critical interactions 
with the immune system and the recent develop-
ment of strategies designed to overcome current 
obstacles to successful therapy.
Naturally occurring oncolytic 
viruses
A group of naturally occurring or attenuated rep-
lication competent oncolytic viruses have been 
identiﬁ  ed, which are non-pathogenic or induce 
only mild symptoms in humans, and possess 
intrinsic tumor selectivity (Roberts et al. 2006). 
This group includes reovirus, a human virus with 
low pathogenicity (TylerKL, 2001), and viruses 
including Newcastle disease virus (NDV) 
(Schirrmacher, 2005), and vesicular stomatitis 
virus (Diaz et al. 2007), for which humans are not 
normally hosts. In order to develop vaccines, 
pathogenic human viruses have been attenuated 
by repeated passage in tissue culture. Some of 
these strains, including measles (Grote et al. 
2001), have acquired the property of oncolytic 
restriction during this process. The use of naturally 
occurring as opposed to genetically modiﬁ  ed 
viruses is advantageous in human therapy in terms 
of regulatory restrictions and safety concerns 
(Chernajovsky et al. 2006).
Genetically Modiﬁ  ed Oncolytic 
Viruses
Viruses use a range of strategies to regulate host 
cellular processes and promote efﬁ  cient replication 
within host cells. Genetic modiﬁ  cation of viruses 
can be used to interfere with these viral strategies, 
preventing replication within normal host 
cells, whilst permitting replication in tumor cells. 
Replacement or modiﬁ  cation of viral promoters 
can provide tumor selectivity (Ko et al. 2005). 
Human DNA viruses, including adenovirus 
(McCormick, 2003), herpes simplex virus (Martuza 
et al. 1991) and vaccinia virus (Zeh and Bartlett, 
2002), have been modiﬁ  ed using recombinant 
technology. This group of DNA viruses are addi-
tionally modiﬁ  ed to attenuate their pathogenicity. 
In addition to safety concerns regarding the use of 
genetically modified viruses, modification to 
reduce pathogenicity can also attenuate anti-tumor 
potency (Gunzburg, 2005).
Mechanisms of Tumor Speciﬁ  city
The process of carcinogenesis involves genetic 
instability, with one estimate of over 11,000 
genomic alterations occurring in a cancer cell 
(Stoler et al. 1999). Neoplastic cells are selected 
for growth advantage, but these mutations can 
lead to defects in anti-viral defences, altered 
expression of receptors, expression of novel 
receptors, and disrupted intracellular signalling 
pathways (Vaha-Koskela et al. 2007). In view of 
these diverse changes, it is perhaps not surprising 
that the tumor speciﬁ  city of oncolytic viruses can 85
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be mediated by an array of different mechanisms, 
and that in many cases the basis of oncolytic 
restriction has been incompletely elucidated 
(Parato et al. 2005). A whole range of mechanisms 
have been exploited to engineer or enhance tumor 
speciﬁ  city (McCormick, 2001). Mechanisms of 
tumor selectivity can be broadly catagorised into 
ﬁ  ve groups: defective anti-viral defences which 
are particularly exploited by naturally oncolytic 
viruses, targeting to receptors unique to or over-
expressed on tumors, the use of tumor or tissue 
speciﬁ  c promoters, viral gene deletions or muta-
tion restricting viral replication in normal tissue, 
and proteolytic processing of viruses in the tumor 
microenvironment.
Defective anti-viral responses
Anti-viral defence mechanisms are inactived in 
many tumors. The double stranded RNA (dsRNA) 
dependant protein kinase (PKR) and type I inter-
feron (IFN) pathways are important, overlapping, 
anti-viral mechanisms in normal cells.
Reovirus is an example of a naturally occurring 
oncolytic virus, whose tumor selectivity involves 
a defective PKR anti-viral response. Reovirus has 
been found to replicate more rapidly in Ras-activated 
cells (Shmulevitz et al. 2005; Coffey et al. 1998). 
In normal cells viral dsRNA induces activation and 
phosphorylation of PKR, which in turn inhibits 
translation of viral transcripts via phosphorylation 
of transcription initiation factor 2α (eIF2α) (de 
Haro et al. 1996). In susceptible Ras-transformed 
cells, PKR is not phosphorylated in response to 
reovirus infection (Strong et al. 1998). In common 
with other oncolytic viruses, the mechanism of 
oncolytic restriction is complex, with recent stud-
ies showing that Ras-transformation enhances viral 
uncoating, infectivity and virion release, in addi-
tion to an effect on the function of PKR (Marcato 
et al. 2007).
The type I interferons, IFNα and IFNβ, have 
anti-proliferative properties, and defects in these 
pathways are commonly found in tumors, promot-
ing cancer growth (Roberts et al. 2006). Several 
oncolytic viruses exploit defects in the IFN path-
ways (Stojdl et al. 2000). For example, NDV is 
able to inhibit IFN signalling in avian but not 
human cells, and is therefore not a human patho-
gen. NDV can however infect and lyse human 
tumor cells lacking an intact type I IFN response 
(Schirrmacher, 2005).
Receptor targeting for tumor selective 
uptake
Viruses can achieve tumor speciﬁ  city if they obtain 
entry to cells via receptors that are overexpressed 
on tumor cells or via mutated receptors that are 
unique to tumor cells. For example, the Edmonton 
strain of measles virus can obtain entry to cells via 
CD46, a receptor which is overexpressed in some 
tumors (Fishelson et al. 2003). Viruses can also be 
retargeted to tumors by modifying virus attachment 
proteins. The measles haemagglutinin (H) attach-
ment protein has been altered to act as a ligand for 
receptors, including growth factor receptors, found 
on tumors (Nakamura et al. 2005). This approach 
relies upon the identiﬁ  cation of tumor-selective 
receptor targets, and ensuring that normal tissues 
are not infected by the modiﬁ  ed virus.
Targeting to tumor or tissue speciﬁ  c 
promoters
Viruses can be genetically modiﬁ  ed to provide 
tumor selectivity by placing regulatory viral genes 
under control of a tumor or tissue speciﬁ  c promoter. 
Promoters for tumor antigens such as prostate 
speciﬁ  c antigen and alphafetoprotein have been 
incorporated into genetically modiﬁ  ed adenovi-
ruses (Hallenbeck et al. 1999; Ko et al. 2005; 
Rodriguez et al. 1997). This approach is, however, 
limited by the weak expression or absence of iden-
tiﬁ  able tumor or tissue speciﬁ  c promoters in most 
cancers.
Genetically engineered virus defects 
permitting replication in tumor cells
Viral genes can be mutated or deleted to provide 
selective replication in tumor cells with abnormal 
cellular pathways. Mutations can allow replication 
in tumor tissue, in contrast to normal tissue, if the 
deleted or mutated viral function can be replaced 
by an altered tumor function. The classic example 
of a deletion providing tumor selectivity is of a 
modiﬁ  ed adenovirus, ONYX-015 (McCormick, 
2003). ONYX-015 was one of the ﬁ  rst modiﬁ  ed 
viruses to enter clinical trials, and is engineered to 
lack the E1B protein. E1B inhibits p53 function, 
preventing anti-viral responses coordinated by p53 
including loss of cell cycling and increased apop-
tosis. ONYX-015 was designed with the concept 
that replication would occur selectively in tumors 
lacking p53, but not in normal cells with intact p53 86
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mechanisms. The mechanism of tumor selectivity 
now appears more complex, with evidence that 
E1B has a function in the export of viral RNA. 
Tumor cells but not normal cells appear to be able 
to provide the missing export function of E1B 
(O’Shea et al. 2004).
Vaccinia virus is another example of a deletion-
modiﬁ  ed virus, with deletion of the viral gene 
thymidine kinase causing loss of the ability to 
synthesise nucleotides. The modiﬁ  ed vaccinia virus 
can only replicate in cycling cells, such as trans-
formed cells, with an abundant supply of nucleo-
tides (Zeh and Bartlett, 2002).
Proteolytic processing of virus particles 
in the tumor microenvironment
Proteolytic disassembly of the outer viral coat is 
required for successful infection by several viruses, 
including reovirus, NDV and adenovirus (Alain 
et al. 2007; Medina-Kauwe, 2003). For example, 
the action of proteases converts reovirus into the 
infectious intermediate sub-viral particles (ISVP). 
Reovirus ISVPs are able to successfully infect cell 
lines which are resistant to intact reovirus (Alain 
et al. 2007). The tumor microenvironment is com-
monly associated with the presence of elevated 
concentrations of proteases, which play a role in 
tumor invasion and metastasis (Mohamed and 
Sloane, 2006). This proteolytic tumor microenvi-
ronment provides the opportunity to enhance the 
tumor selectivity, by modifying the viruses to be 
dependant upon the action of proteases for optimal 
infectivity. For example the fusion (F) protein of 
measles virus, which facilitates entry into cells, 
has been modiﬁ  ed such that it requires the action 
of matrix metalloproteinase 2 for conversion into 
the functional form (Maisner et al. 2000).
Animal Models
Animal models are widely used prior to new 
therapies entering human clinical trials, although 
their limitations are well recognised (Mestas and 
Hughes, 2004). The use of animal systems when 
investigating oncolytic viruses is particularly 
problematic in view of species variability in the 
efﬁ  ciency of infection and pathogenicity (Vaha-
Koskela et al. 2007). This has led to the use of 
immunocompromised human xenograft models, 
which inevitably are unable to accurately predict 
the interaction between virotherapy and an 
immunocompetant host. Consequently animal 
models can only provide a limited insight 
regarding efﬁ  cacy and toxicity of human onco-
lytic virotherapy.
Clinical Experience with Oncolytic 
Viruses
The experience from clinical trials using oncolytic 
viruses has been summarised by Aghi et al. (Aghi 
and Martuza, 2005). For use in clinical studies 
manufacture of the virus according to the principles 
of Good Manufacturing Practices to a high titre 
must be possible. Several different oncolytic 
viruses have entered modern clinical trials since 
1996, including naturally oncolytic reovirus, NDV 
and Coxsackievirus, attenuated and modified 
measles virus, and engineered adenovirus, vac-
cinia, and HSV. Administration routes have 
included intratumoral injection, systemic and 
intracavitary delivery. Overall clinical data sug-
gests a limited degree of efﬁ  cacy with several 
oncolytic viral therapies. For example, ONYX-015 
has entered a series of clinical trials, with local 
tumor regression rates of between 0–14% (Kirn, 
2001). This level of anti-tumor activity, although 
low, provides encouragement for future oncolytic 
viral therapy if the route of administration, potency, 
tumor selectivity and immune interactions can be 
optimised. In contrast to conventional phase I drug 
trials, the maximum tolerated dose of virus is com-
monly not reached, and dose is limited by techni-
cal restrictions in the quantity of virus which can 
be produced (Parato et al. 2005). Replication com-
petent viruses do not have a straightforward dose 
response relationship for efﬁ  cacy or toxicity, and 
the optimum dosing regimens for most viruses 
remain unclear. If the virus is able to rapidly rep-
licate in a tumor, it may only be necessary for a 
low viral load to infect tumor tissue. Anti-viral 
humoral immune responses may confound dose 
effects. Evidence of a dose response exists for the 
use of systemically administered NDV, although 
not for some other viruses including HSV (Aghi 
and Martuza, 2005).
The majority of clinical studies have adminis-
tered virus via intratumoral injections (Liu and 
Kirn, 2007). Mechanisms which provide viruses 
with tumor selectivity do not completely preclude 
infection of normal tissue and consequent toxicity. 
Intratumoral delivery of oncolytic viruses provides 
a further direct physical restriction to enhance 
tumor selectivity. Considerable safety data has 87
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been obtained from these studies, and local delivery 
of viral therapy is generally very well tolerated, 
with the most common side effects being mild 
‘ﬂ  u-like symptoms and a minor local reaction 
(Kirn, 2001). There has been evidence of clinical 
activity in some of these early clinical studies, 
ranging through stable disease, marker responses, 
to partial and occasional complete responses (Aghi 
and Martuza, 2005). Studies with intratumoral 
administration have generally not demonstrated 
activity against distant non-injected lesions (Liu 
and Kirn, 2007), greatly limiting the potential of 
local viral therapy in the treatment of metastatic 
disease. In an exception to this observation, in 
patients with metastatic melanoma receiving intra-
tumoral injections of GM-CSF armed vaccinia 
virus (JX-594, JENNEREX), regressions in distant 
non-injected dermal metastases were noted in four 
of seven patients treated (Mastrangelo et al. 1999). 
These regressing lesions were found to be heavily 
inﬁ  ltrated by T lymphocytes. Similarly, in a phase 
I study of intratumoral administration of a modiﬁ  ed 
HSV expressing GM-CSF, non-injected distant 
tumor sites became inﬂ  amed in 4 of 30 patients 
(Hu et al. 2006).
A limited number of studies have investigated 
intravenous delivery of virus. Studies using intra-
venous administration of the modiﬁ  ed adenovi-
ruses have not shown systemic activity (Liu and 
Kirn, 2007). Systemic efﬁ  cacy following intrave-
nous administration has however been demon-
strated using NDV (Lorence et al. 2003) and 
reovirus (Stoeckel and Hay, 2006; Spicer et al. 
2007). In a phase I study of intravenously admin-
istered reovirus in patients with advanced cancer, 
viral replication was demonstrated in post-treatment 
tumor biopsies and stable disease was reported in 
6 of 32 evaluable patients (Spicer et al. 2007), 
demonstrating the feasibility of systemic viral 
delivery to tumors. Systemic delivery is associated 
with more severe ‘ﬂ  u-like symptoms, although the 
toxicity proﬁ  le remains favourable compared with 
conventional cancer therapy. Dose schedule inﬂ  u-
ences toxicity, with a prolonged infusion time 
reducing toxicity following systemic delivery of 
NDV (Hotte et al. 2007). Observations with dose 
schedules with one virus are not necessarily appli-
cable to other viruses. One treatment-related death 
has been reported, in a patient with reduced lung 
capacity, following treatment with a naturally 
modiﬁ  ed NDV. Post-mortem examination sug-
gested that rapid tumor lysis had led to respiratory 
failure (Pecora et al. 2002). Similar to conventional 
cancer therapy, this case demonstrates the need for 
adequate performance status and functional 
reserve.
Clinical Lessons Learnt from 
Important Oncolytic Viruses
Onyx-015
One of the most studied oncolytic viruses to date 
is Onyx-015. This E1B gene deleted adenovirus 
was the ﬁ  rst oncolytic viral agent to be tested in 
humans and over 200 cancer patients have so far 
been treated in over 15 clinical trials (phases 
I-III)(Kirn, 2001). It was developed on the hypoth-
esis that an adenovirus with a deletion in the p53-
inhibitory gene E1B would replicate in tumours 
in which p53 was defective (Bischoff et al. 
1996). As it was the ﬁ  rst agent of its kind to be 
tested in humans it was deemed important to assess 
biological data on a viral replication and antiviral 
immune responses in the initial clinical trials 
(Kirn, 2001). A staged approach to clinical devel-
opment was adopted in which the virus was ﬁ  rst 
tested intratumorally to assess it safety and bio-
logical activity and then subsequent trials studied 
administration via intraperitoneal, intra-arterial 
and eventually intravenous administration. The 
virus was well-tolerated at the highest doses that 
could be administered (2 × 10
12– 2 × 10
13 viral 
particles), within the limits of viral manufacture, 
by all routes. Flu-like symptoms were the most 
common toxicities and were increased in patients 
receiving vascular administration. There was no 
clear correlation between the development of ﬂ  u-
like symptoms and viral dose or dose administra-
tion regimen. Neutralizing antibodies were 
generated following all routes of administration 
and viral doses. Interestingly, following intra-
peritoneal delivery to patients with ovarian cancer, 
toxicity including viraemic symptoms and abdom-
inal pain appeared more commonly in patients 
with bulky disease (Vasey et al. 2002). As the 
access of intraperitoneally administered drugs into 
solid tumour nodules is limited and retention of 
the virus within the abdominal cavity was gener-
ally of short duration, it was postulated that intra-
peritoneal viral therapy is most likely to efﬁ  cacious 
in patients with low tumour burden (Vasey et al. 
2002). In these patients the severity of ﬂ  u-like 88
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symptoms was unrelated to the presence or 
absence of pre-exisiting neutralizing antibodies. 
Antitumoral activity was demonstrated using 
single agent Onyx-015 intra-tumoral therapy in 
head and neck cancer, although the response rate 
was only 13% following repeated treatment 
(Nemunaitis et al. 2000; Kirn, 2001). These 
responses did not correlate with neutralizing anti-
body levels, potentially due to the inefﬁ  cient 
penetration of antibodies into tumor masses 
(Baxter et al. 1994). No objective responses with 
single agent therapy occurred in patients with 
pancreatic, colorectal or ovarian cancers. In view 
of the rarity of clinical responses to Onyx-015 
combination therapy with chemotherapy was 
explored. As discussed later, a synergistic interac-
tion with chemotherapy in multiple tumours types 
and by multiple routes of administration was 
observed (Heise et al. 1997; Kirn, 2001).
HSV1716
HSV1716 is an engineered oncolytic virus which 
lacks copies of the gene encoding the virulence 
factor ICP34.5 (Dolan et al. 1992) such that it will 
only replicate in actively dividing cells and not 
terminally differentiated cells (Brown et al. 1994). 
HSV1716 has been shown to be safe when admin-
istered intratumorally in patients with recurrent 
high-grade glioma (HGG) (Rampling et al. 2000) 
and metastatic melanoma (MacKie et al. 2001). In 
both tumours the virus has been shown to replicate 
without causing toxicity in both HSV seropositive 
and seronegative patients (MacKie et al. 2001; 
Papanastassiou et al. 2002). Prior exposure to HSV 
does not therefore preclude therapy with HSV1716. 
Studies in patients with HGG have gone on to 
explore combination with surgical debulking, with 
HSV1716 injected into the rim of the surgical 
resection cavity, followed by chemotherapy and/or 
radiotherapy as clinically indicated (Harrow et al. 
2004). Again no toxicity was evident, and there 
were encouraging suggestions of prolonged sur-
vival in some patients with this poor prognosis 
tumour. The authors have postulated that the 
inﬂ  ammatory environment post-surgery may limit 
viral replication, and that virus delivery optimisa-
tion remains critical to the future success of this 
therapeutic approach (Harrow et al. 2004). As with 
Onyx-015, the experience with HSV1716 is sug-
gestive of the potential therapeutic benefit of 
combined modality treatment.
Safety
Despite the clinical experience of a favourable 
toxicity proﬁ  le with high viral doses, compared 
with the toxicity of conventional cytotoxic thera-
pies, safety concerns remain concerning the use of 
replicating oncolytic viral therapy. In contrast to 
gene therapy with non-replicating adenovirus or 
retrovirus vectors, the interactions of replicating 
virus with both host and environment are far more 
difﬁ  cult to predict. Live replicating virus can be 
shed from patients following treatment, raising the 
possibility of person-to-person transmission. For 
example NDV has been isolated from urine up to 
three weeks after treatment (Pecora et al. 2002). 
The mutation rate of viruses is high, more so in the 
case of RNA viruses (Chernajovsky et al. 2006). 
Even if the administered virus does not represent 
a human pathogen, there is the theoretical possibil-
ity that the virus may mutate to acquire pathogenic 
properties and successfully infect normal host tis-
sues or bystanders. Modiﬁ  ed viruses may revert to 
wild-type, and additionally may recombine with 
wild-type viruses (Chernajovsky et al. 2006). In 
order to avoid such scenarios, viruses have been 
attenuated by mutations and deletions. Unfortu-
nately, attenuated viruses may also lose anti-tumor 
potency (Gunzburg, 2005). Pro-drug activating 
suicide genes have been incoporated into some 
modiﬁ  ed viruses as a safety mechanism in order 
to eliminate infected cells in case infection runs 
out of control (Gunzburg, 2005). Therapeutic 
strategies to improve oncolytic virotherapy include 
enabling the virus to evade immune-mediated 
clearance, potentially circumventing the immune 
barrier to unwanted viral spread. It is important 
that consideration of these safety issues continues 
to inﬂ  uence the development of oncolytic viral 
therapy.
The Potential of Oncolytic Viruses 
to Induce Anti-Tumor Immunity
Despite intensive investigation of the direct cyto-
toxic ability of oncolytic viruses, little attention has 
been given to the potential to induce anti-tumor 
immunity. Matzinger has proposed that the key role 
of the immune system is not primarily the identiﬁ  -
cation of self and non-self, but the recognition of 
‘danger’ signals (Matzinger, 1994). Virus-induced 
cell death is expected to create an inﬂ  ammatory 
‘dangerous’ environment, with pro-inﬂ  ammatory 
cytokine release, the presence of toll-like receptor 89
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(TLR) ligands and inﬁ  ltration of cells of the innate 
immune system (Matzinger, 1998; Zeng et al. 2002; 
Alexopoulou et al. 2001). The immune response to 
a foreign challenge involves both the innate and 
acquired arms of the immune system, with the 
innate immune response guiding subsequent antigen 
speciﬁ  c adaptive immunity (Gallucci and Matzinger, 
2001). In addition to this ‘dangerous’ context, 
virally-induced lysis of tumor cells will release a 
wide range of tumor associated antigens (TAA) into 
the microenvironment. Inﬁ  ltrating dendritic cells 
can process released TAA, migrate to lymph nodes, 
cross-present antigen to T cells, and potentially 
generate an adaptive anti-tumor immune response 
(Toda et al. 1999).
The inﬂ  ammatory context created by virus-
induced cell death is more likely to produce a 
stimulatory immune response as opposed to toler-
ance (Schirrmacher, 2005). However, due to the 
immunogenicity of viral antigens, an anti-viral 
adaptive immune response may rapidly clear virus 
and inhibit the development of anti-tumor immu-
nity. In addition, the ability to prime an effective 
anti-tumor adaptive immune response is dependant 
upon the ability of dendritic cells to cross present 
TAA in an appropriate costimulatory context to T 
cells (Banchereau et al. 2001), and many viruses 
are recognised to interfere with DC function as part 
of their immune evasion mechanisms (Pollara 
et al. 2005).
There is some limited data regarding the ability 
of oncolytic viruses to generate an anti-tumor 
immune response, drawn from animal models, 
in vitro human systems and clinical trials.
Animal models
Different modified strains of HSV have been 
shown to induce systemic anti-tumor immune 
response in murine models (Toda et al. 1999; Li 
et al. 2007a; Li et al. 2007b). In one of these stud-
ies, in mice with established bilateral colorectal or 
melanoma tumors, unilateral intratumoral injection 
of an attenuated strain of HSV elicited a reduction 
in the size of the contralateral uninjected tumor, 
associated with generation of CD8 T cells speciﬁ  c 
to a tumor antigen (Toda et al. 1999). Diaz et al. 
(Diaz et al. 2007) used VSV in a B16ova murine 
melanoma model, ﬁ  nding in cellular depletion 
studies that intact CD8+ T cells and natural killer 
cells are critical to the efﬁ  cacy of intratumoral VSV 
therapy. CD8+ cells were detected both to viral 
epitopes and to the SIINFEKL epitope of the model 
tumor antigen, OVA. In a tumor vaccination rat 
model, an oncolytic virus parvovirus H-1 was 
found to enhance the ability of lethally irradiated 
autologous tumor cells to suppress tumor growth 
(Raykov et al. 2007).
In vitro human systems
Moehler et al. (Moehler et al. 2005) used an in vitro 
allogeneic human system to provide ‘proof of 
principle’ that oncolytic virus-induced cell death 
can lead to cross presentation of TAAs. Tumor cell 
lysates induced by parvovirus H-1 stimulated DC 
maturation and cross presentation of melanoma 
antigens to CTL clones, in contrast to tumor cell 
lysates induced by ultraviolet light or freeze-thaw 
cycles. Greiner et al. (Greiner et al. 2006) investi-
gated the ability of a highly attenuated modiﬁ  ed 
vaccinia virus to prime an adaptive anti-tumor 
response. Dendritic cells cocultured with an allo-
geneic melanoma cell line infected by the modiﬁ  ed 
virus were able to induce a mixed leukocyte 
response, and to prime autologous T cells to gener-
ate an interferon response to a melanoma TAA, 
MelanA. In contrast, an unattenuated wild type 
strain of the vaccinia virus, Western Reserve (WR) 
inhibited DC maturation (Jenne et al. 2000) and 
was not capable of priming an immune response.
Clinical strategies
Oncolytic viruses have been incorporated into dif-
ferent strategies with the aim of generating anti-
tumor immunity.
Ex vivo oncolysates
Oncolytic viruses have been incorporated into 
tumor vaccine preparations in an attempt to enhance 
their immunogenicity. Phase II trials investigating 
the use of vaccinia virus melanoma cell lysates in 
the adjuvant setting following resection of mela-
noma suggested highly significant survival 
improvements compared with historical melanoma 
patient controls (Hersey et al. 1987). Disappoint-
ingly a subsequent phase III study of 700 patients 
failed to show any improvement in recurrence or 
overall survival (Hersey et al. 2002).
Schirrmacher et al. (Schirrmacher, 2005) have 
performed a series of clinical vaccine studies using 
a live autologous tumor vaccine, infected by NDV, 
followed by high dose irradiation to render tumor 
cells non-viable. Using skin prick tests following 90
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NDV autologous tumor vaccinations, a signiﬁ  cant 
number of patients developed a speciﬁ  c anti-tumor 
delayed type hypersensitivity memory response. 
A variety of phase II studies have subsequently 
been performed to evaluate clinical efficacy 
of this vaccination approach. Studies in colorectal 
cancer (Schlag et al. 1992), glioblastoma 
multiforme (Steiner et al. 2004), malignant 
melanoma (Schirrmacher et al. 1998), and breast 
cancer (Schirrmacher, 2005) have demonstrated 
statistically signiﬁ  cant improvements in overall 
survival by 20–36% at 2–5 year follow up. These 
observed improvements in survival lend support 
to the theory that the danger signal provided by 
oncolytic viruses may break tumor immune 
tolerance, but as demonstrated by the experience 
with vaccinia virus, prospective phase III trials are 
required.
In situ tumor injection
In clinical studies, the previously discussed regres-
sion of non-injected distant melanoma deposits with 
associated lymphocyte inﬁ  ltrate following intratu-
moral administration of the JX594 modiﬁ  ed vac-
cinia virus suggests the possible development of 
anti-tumor immunity (Mastrangelo et al. 1999).
Other investigators have started to extend vac-
cine strategies by arming viral vectors with cyto-
kines and immune costimulatory molecules 
(Mastrangelo and Lattime, 2002). Successful trans-
fection into tumors has been achieved, although 
with no convincing clinical beneﬁ  t to date.
Vaccination approaches using viruses 
transduced with TAA
TAAs have been transduced into viruses in order 
to enhance the prospect of generating anti-tumor 
immunity as opposed to anti-viral immunity. In a 
phase I/II study of non-replicating vaccinia virus 
expressing melanoma antigens along with costim-
ulatory molecules, melanoma antigen specific 
lymphocytes were expanded (Zajac et al. 2003).
Combination Therapy
Combination therapy utilising virotherapy may 
be beneﬁ  cial if the treatments used lack cross-
resistance, have non-overlapping toxicity or 
demonstrate synergistic effects on tumor kill. The 
action of radiotherapy or chemotherapy in combi-
nation with virotherapy is likely to be complex, 
with interactions occurring at a cellular level, upon 
tumor structure and intratumoral barriers to viral 
spread, and immune modulatory/suppressive 
effects.
Radiotherapy
Intratumoral virotherapy can be combined with 
radiotherapy with the aim of enhancing locore-
gional control. In preclinical studies there is an 
increasing body of evidence that radiotherapy can 
synergise with viral oncolytic therapy (Advani 
et al. 2006). For example, radiotherapy and 
modiﬁ  ed HSV variants demonstrate supra-addi-
tive cell kill in in vitro assays of human cervical 
cancer (Blank et al. 2002) and colorectal cancer 
(Stanziale et al. 2002). Cellular changes induced 
by irradiation can enhance the ability of viruses 
to replicate and spread within a tumor. In a human 
glioma xenograft model irradiation combined 
with a modiﬁ  ed HSV produced greater tumor 
reduction than either treatment alone, and an 
increased viral load was recovered in irradiated 
grafts (Advani et al. 1998). Similar interactions 
have been reported between oncolytic adenovirus 
vectors and radiotherapy. Combined therapy with 
ONYX-015 and radiotherapy increased tumor 
growth delay compared with either treatment 
alone in a colorectal xenograft model (Rogulski 
et al. 2000). A completed phase I study combining 
intratumoral injections of reovirus with radiation 
has demonstrated the feasibility of combination 
virotherapy with fractionated radiotherapy regi-
mens, and phase II studies are currently underway 
(Harris et al. 2007).
Chemotherapy
Synergy has been demonstrated between modiﬁ  ed 
adenoviruses and chemotherapeutic agents (Kirn, 
2001). Anti-tumor efﬁ  cacy was greater in a human 
xenograft tumor model following administration 
of ONYX-015 with cisplatin or 5-ﬂ  uorouracil than 
with either agent alone (Heise et al. 1997). Based 
upon encouraging pre-clinical and phase I and II 
data, a modiﬁ  ed ONYX-015 adenovirus vector has 
been combined with cisplatin and 5-ﬂ  uorouracil 
chemotherapy in the treatment of squamous cell 
carcinoma of the head and neck or oesophagus in 
a phase III trial. The response rate with viral com-
bination therapy of 79% was signiﬁ  cantly greater 
than that with chemotherapy alone of 40% (Xia 
et al. 2004).91
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Obstacles and Solutions to the 
Design of Successful Oncolytic 
Viral Therapy
Regardless of the mechanisms of tumor selectivity 
possessed by a virus, therapeutic quantities of virus 
must enter the tumor, spread throughout the tumor, 
and evade immune-mediated viral clearance long 
enough to mediate a useful anti-tumor effect. In 
view of the inability of intratumorally delivered 
virus to spread to other tumor sites, effective sys-
temic delivery remains a critical goal for the treat-
ment of metastatic disease.
Virus delivery
The natural host infection route of many viruses 
involves entry via the skin or mucosa, and viruses 
are often not adept at survival in the circulation. 
Evading a series of host defences which remove 
virus from the circulation is a major challenge for 
achieving successful systemic administration.
Viruses within the bloodstream are subject to 
non-speciﬁ  c interactions with blood cells, non-
target tissue, the reticulo-endothelial system and 
complement. Within the blood stream virus par-
ticles interact with and bind to circulating blood 
cells. Binding to blood cells may impair delivery 
of virus to target tissue. In one experimental sys-
tem, the binding of an adenovirus to human blood 
cells compromised delivery to tumor (Lyons 
et al. 2006). In contrast, binding of virus to blood 
cells may shield the virus from other mechanisms 
of clearance, increasing survival in the circulation 
and allowing for increased interactions with the 
tumor microcirculation (Cole et al. 2005). Virus 
particles also adhere to non-blood cells with which 
they come into contact, removing them from the 
blood (Pizzato et al. 1999). Circulating virus par-
ticles are vulnerable to uptake by the reticuloen-
dothelial system (Ye et al. 2000; Worgall et al. 
1997). The liver, in particular, has multiple mech-
anisms by which virus particles are cleared (Fisher, 
2006). The specialised macrophages within the 
liver, known as Kupffer cells, are likely to play a 
predominant role in virus removal via scavenger 
receptors (Worgall et al. 1997). Blood ﬂ  ow through 
the liver is high, and efﬁ  cient removal of virus 
particles by the liver will result in a very short 
survival in the circulation (Ye et al. 2000). The 
alternative complement pathway additionally con-
tributes to virus neutralisation in the plasma 
(Devaux et al. 2004; Wakimoto et al. 2002).
In addition to non-speciﬁ  c interactions which 
mediate viral clearance, virus particles are cleared 
from the circulation by antibody interactions. 
Anti-viral antibodies are generated by the adap-
tive humoral immune response to circulating virus 
(Parato et al. 2005), and may neutralise virus 
particles by binding to the surface of the virus 
and preventing viral binding to receptors mediat-
ing cellular entry (Tsai et al. 2004; Chen et al. 
2000). Non-neutralising antibody binding to virus 
particles enhances virus targeting by complement 
and uptake by cells bearing Fc receptors (Fisher, 
2006). Anti-viral antibodies may pre-exist due to 
prior viral exposure, and represent a major hurdle 
to systemic virotherapy. For example, more than 
50% of individuals have prior exposure to reovi-
rus infection as demonstrated by the presence of 
anti-reovirus antibody (TylerKL, 2001). Almost 
all individuals have circulating anti-measles anti-
body due to prior vaccination or infection which 
rapidly neutralises measles virus (Iankov et al. 
2007). In addition, an adaptive immune response 
following treatment generates an antibody 
response impairing subsequent virus delivery.
Although much initial research focussed upon 
the tumor selectivity of oncolytic viruses, it is now 
becoming increasingly clear that these host mech-
anisms, by which virus is cleared from the circula-
tion, can prevent signiﬁ  cant viral infection of tumor 
targets. A host of potential solutions, in addition to 
route of delivery, are under investigation to enhance 
virus delivery.
Delivery using cell carriers
The use of infected cell carriers represents a novel 
strategy to allow virus delivery, ‘shielding’ virus 
from neutralising antibody (Thorne et al. 2006; 
Power et al. 2007; Ong et al. 2007; Raykov et al. 
2004). Virus may be released into the tumor in 
response to features of the tumor environment 
(Harrington et al. 2002; Cole et al. 2005). In vivo 
models have demonstrated the ability of infected 
monocytic, endothelial, stimulated peripheral 
blood cells and T cells to deliver measles virus to 
tumors, in the presence of neutralising antibodies, 
by a process of cell-to-cell heterofusion induced 
by the measles virus (Iankov et al. 2007; Ong 
et al. 2007). Similarly, leukaemic, tumor-derived 
and xenogenic cell carriers infected with VSV 
efﬁ  ciently delivered virus to tumors in model 
systems, despite the presence of neutralising 92
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antibody (Power et al. 2007). Prior to administration 
in humans these potentially oncogenic cell carri-
ers would need to be inactivated. Thorne et al. 
(Thorne et al. 2006) utilised cytokine induced 
killer cells (CIK) as cell carriers for oncolytic 
vaccinia virus in a murine model. CIK cells are 
immune cells induced by cytokines ex vivo, with 
anti-tumor activity and an ability to trafﬁ  c to 
tumor sites. This dual approach aims to exploit a 
synergy between virotherapy and cellular therapy. 
Compared with non-cellular methods of virus 
delivery, the use of live carrier cells has the poten-
tial advantage of viral replication within the car-
rier cell, leading to the release of an ampliﬁ  ed 
quantity of virus within the tumor environment 
(Power et al. 2007). Retroviral particles have been 
found to non-speciﬁ  cally adhere or ‘hitch-hike’ 
on the surface of T cells, allowing cellular deliv-
ery to the tumor in immunocompetant murine 
models (Cole et al. 2005). The viral particles are 
released in the tumor microenvironment, in a 
process enhanced by T cell activation and by 
heparinase produced by tumor cells. A similar 
phenomenon has been observed with other viruses 
(Blomer et al. 2005; Geijtenbeek et al. 2000). If 
oncolytic viruses can be similarly ‘hitch-hiked’, 
future potential therapy may combine adoptive T 
cell transfer with virotherapy.
Modiﬁ  cation of virus particles to evade 
clearance
The surface of virus particles, in particular adenovirus, 
have been modiﬁ  ed physically and chemically to 
mask the viral protein coat, enabling evasion of host 
clearance mechanisms (Fisher, 2006). These methods 
are based upon similar strategies designed to reduce 
drug elimination, although application to virus 
particles is technically challenging (Fisher, 2006). 
Examples include encapsulation in a polymer coating 
(Green et al. 2004; Fisher et al. 2001), microspheres 
(Matthews et al. 1999) and polyethylene glycol 
(PEG) (Croyle et al. 2002). Modification can 
abrogate the ability of viruses to bind to their cellular 
targets, although ligands to enhance targeting can be 
incorporated into the encapsulation (Stevenson et al. 
2007). In other cases modiﬁ  cation does not prevent 
target infection (O’Riordan et al. 1999).
Serotype switching
The anti-viral humoral immune response can pre-
vent effective repeat adminstrations of an oncolytic 
virus. For some viruses, including VSV and 
adenovirus, multiple serotypes exist for which 
neutralising antibodies do not have cross reactivity 
(Russell, 2002; Bangari and Mittal, 2006). Different 
serotypes can be sequentially administered, in a 
process termed serotype switching, to prevent anti-
body neutralisation.
Immunosuppression
Immunosuppressive drugs can be used to inhibit the 
development of antiviral immunity and early viral 
elimination. In a murine study of intratumoral reo-
virus therapy for colorectal liver metastases the 
therapeutic efﬁ  cacy of reovirus was enhanced by 
immunosuppression by cyclosporin A (Smakman 
et al. 2006). Another immunosuppressive agent, 
cyclophosphamide, has been shown to enhance 
HSV oncolytic therapy in a glioma model, by inhib-
iting infiltration by phagocytic cells (Fulci 
et al. 2006). The immune system has complex 
effects upon viral therapy, and immunosuppression 
would be expected to reduce the possibility of gen-
erating anti-tumor immunity following oncolytic 
virotherapy. The impact of immunosuppression is 
likely to be virus and tumor model speciﬁ  c.
Inhibition of liver uptake
A novel strategy to enhance the duration of virus 
circulating in the blood is to inhibit liver uptake 
(Fisher, 2006). Agents cytotoxic to the Kupffer 
cells of the liver, such as liposomes containing 
clodronate, can temporarily inhibit viral uptake 
(Schiedner et al. 2003).
Barriers to spread of virus within the 
tumor
In the same manner as drug therapy, systemically 
administered virotherapy must cross the endothe-
lial lining of blood vessels to enter the tumor 
interstitium, travel through extracellular matrix 
(ECM), basement membrane and necrotic areas, 
to access tumor cells (Molema et al. 1997). Tumor 
vasculature is disordered, with wide fenestrae and 
discontinuous basement membranes (Jain, 1987). 
Tumor size and connective tissue, however, pose 
signiﬁ  cant impediments to viral spread through the 
tumor (Li et al. 2004). Oncolytic viruses are larger 
than conventional drugs, varying from 20–300 nm 
(Fisher, 2006). The diffusion of larger viruses, such 
as HSV, are signiﬁ  cantly restricted by the ECM 93
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(McKee et al. 2006). The tumor microenvironment 
is highly heterogenous, with areas of hypoxia and 
acidosis, which can affect the virus target cell 
interaction (Vaha-Koskela et al. 2007). The pattern 
of tumor infection by oncolytic viruses, whether 
delivered intratumorally or systemically is heter-
ogenous (Sauthoff et al. 2003; Kim et al. 2006; 
Shayakhmetov et al. 2002). For example although 
high levels of adenovirus persist in xenograft tumor 
tissue 8 weeks after intratumoral injection, distribu-
tion is patchy (Sauthoff et al. 2003).
Strategies designed to enhance the delivery of 
drugs to tumors (Minchinton and Tannock, 2006) 
can be applied to oncolytic viruses. Treatment of 
the tumor ECM by proteases could enhance virus 
spread (Kim et al. 2006; Kuriyama et al. 2000). An 
ECM degredation protein relaxin, expressed by an 
engineered adenovirus vector, increased tumor 
penetration by the virus and inhibited tumor growth 
in a xenograft model (Kim et al. 2006). Fusogenic 
membrane glycoproteins (FMG) are proteins 
involved in the entry of several types of virus, 
including measles and VSV into cells. FMGs induce 
widespread cell-to-cell fusion and the formation of 
giant syncitia (Bateman et al. 2000), which may 
enhance the ability of a virus to overcome the intra-
tumoral barriers to spread (Ahmed et al. 2003).
Conclusion
Oncolytic viruses are tumor selective potent anti-
cancer agents. Currently in the early stages of their 
emergence as useful therapy, their promise is yet 
to be fulﬁ  lled. Clincial studies so far have provided 
evidence of limited activity both following local 
and systemic administration. Human tumors are 
very diverse, and the response to virotherapy is 
variable. Signiﬁ  cant challenges remain to be over-
come before oncolytic viruses can emerge as 
broadly useful therapy. Efforts are being made to 
enhance the anti-tumor potency of oncolytic 
viruses, whilst maintaining tumor selectivity. The 
anti-viral immune response is a major obstacle to 
effective virotherapy, although the release of TAAs 
and provision of a ‘danger’ signal offer the tanta-
lising possibility of generating anti-tumor immu-
nity. Rapid clearance of virus from the bloodstream 
has limited systemic application. A host of differ-
ent solutions, including cellular carriers and 
modification of virus particles, have recently 
emerged to enhance systemic delivery. Oncolytic 
viruses have a favourable toxicity record, and 
safety concerns regarding the use of live replicating 
viruses continue to be addressed. A lack of cross-
resistance, non-overlapping toxicity, and evidence 
of synergistic interactions with radiotherapy and 
chemotherapy lays the basis for future combina-
tion virotherapy treatment. The considerable 
concerns by institutions worldwide as to the toxic-
ity of these agents to patients, staff, patients’ 
immediate relatives and shedding into the environ-
ment have resulted in more deﬁ  ned regulatory 
guidelines and appropriate risk assessments. This 
process combined with the considerable costs 
when compared to standard cancer chemothera-
peutics has led to questioning of the viability of 
virus based approaches. Despite this scrutiny, it is 
clear that oncolytic viruses are moving closer to 
fulﬁ  lling their exciting clinical potential and may 
become the standard of care for certain cancer 
scenarios in the future.
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